|drug1803||Hydroxychloroquine Sulfate 600 mg once a day Wiki||1.00|
|drug1804||Hydroxychloroquine Sulfate 600 mg twice a day Wiki||1.00|
|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study testing different doses of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.
Description: Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 days have elapsed since the beginning of symptom onset.Measure: Median release from quarantine time Time: 14 days or less
Description: Cohort 2 (hospitalized COVID-19 patients): Rate of participants discharged at or before 14 daysMeasure: Rate of hospital discharge Time: 14 days
Description: Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 monthsMeasure: Rate of infection Time: 2 months
Description: Cohort 1 rate of participant-reported secondary infection of housematesMeasure: Rate of housemate infection Time: 14 days
Description: Cohort 1 rate of hospitalizationMeasure: Rate of hospitalization Time: 14 days
Description: Cohort 1 rate of treatment related adverse eventsMeasure: Cohort 1 adverse event rate Time: 14 days
Description: Cohort 2 Time to condition appropriate for discharge. The primary care team indicates the patients has improved to the point of being discharged.Measure: Time to condition appropriate for discharge Time: 14 days
Description: Cohort 2 rate of ICU admission from a floor bed in the hospitalMeasure: Rate of ICU admission Time: 14 days
Description: Cohort 2 the number of days between hospital admission and a negative PCR test for SARS-CoV-2.Measure: Time to PCR negativity Time: 14 days
Description: Cohort 2 rate of treatment related adverse eventsMeasure: Cohort 2 adverse events Time: 14 days
Description: Cohort 3 number of scheduled shifts at the hospital that are missed.Measure: Scheduled shifts missed Time: 2 months
Description: Cohort 3 rate of treatment related adverse eventsMeasure: Cohort 3 adverse events Time: 2 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports